Chemistry:Eganelisib

Short description: Chemical compound

Eganelisib

Clinical data
Pregnancy category	US: N (Not classified yet)
Routes of administration	Oral
ATC code	None
Identifiers
IUPAC name 2-amino-N-[(1S)-1-{8-[(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl}ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
CAS Number	1693758-51-8
PubChem CID	91933883
ChemSpider	60600433
UNII	FOF5155FMZ
KEGG	D11896
ChEMBL	ChEMBL3984425
PDB ligand	V7Y (PDBe, RCSB PDB)
Chemical and physical data
Formula	C30H24N8O2
Molar mass	528.576 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cn1cc(cn1)C#Cc6cccc2c6C(=O)N(C(=C2)C(C)NC(=O)c4c3ncccn3nc4N)c5ccccc5
InChI InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1 Key:XUMALORDVCFWKV-IBGZPJMESA-N

Eganelisib (USAN), codenamed IPI-549, is an experimental drug being investigated as a possible treatment for cancer. It is a highly selective phosphoinositide 3-kinase inhibitor, and thus works by inhibiting the enzyme PIK3CG, disrupting the PI3K/AKT/mTOR signaling pathway which plays important roles in the development of cancer.

Eganelisib is being developed by Infinity Pharmaceuticals. Early clinical trial results were published in September 2016. On September 29, 2020, it was granted Fast Track designation by the United States Food and Drug Administration (FDA) as a treatment for inoperable, locally advanced, or metastatic triple-negative breast cancer, combined with a checkpoint inhibitor and chemotherapy.

(As of October 2020), five phase I/II clinical trials were ongoing in the United States, and one in Europe.

Further reading

• "Discovery of Potent and Selective PI3Kγ Inhibitors". J Med Chem 63 (19): 11235–11257. October 2020. doi:10.1021/acs.jmedchem.0c01203. PMID 32865410.